ID | Study design | Search methods and years | Research question or aim | Number of studies included | Type of study | Population/Type of GIST | Patients (N) | AMSTAR Score | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RCT | NRT | NCS | Cohort | CC | SC | ||||||||
Abdel-Rahman 2015 | SR | Standard searcha; through July 2014. | To assess the available evidence for systemic therapy options for patients with advanced gastrointestinal stromal tumours beyond first-line imatinib. | 26 | 6 | 0 | 15 | 5 | 0 | 0 | Adults/Advanced GIST. | 935 | 6 |
Chen 2014 | SRM | Standard search; through June 2014. | To compare short-term and long-term results of patients undergoing laparoscopy surgery. | 22 | 0 | 0 | 0 | 22 | 0 | 0 | Adults/Localised GIST. | 1166 | 9 |
Crona 2013 | SR | Standard search; through August 2013. | To review the preclinical and clinical literature that led to the approval of regorafenib and to examine its place in therapy for the treatment of mCRC and GIST. | 2 | 1 | 0 | 1 | 0 | 0 | 0 | Adults/Advanced, unresectable and/or metastatic GIST. | 233 | 5 |
Cirocchi 2010 | SRM | Followed Cochrane Collaboration metodology; through June 2009. | To compare surgery alone with the use of imatinib as preoperative supplement for unresectable and/or metastatic GIST. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Adults/Unresectable and/or metastatic GIST. | 901a | 6 |
Essat 2011 | SR | Standard search; through August 2009. | To evaluate the efficacy and safety of imatinib for the adjuvant treatment of adult patients with localised KIT (CD117)-positive GIST after complete surgical resection relative to current standard treatment (surgery without adjuvant therapy). | 16 | 1 | 0 | 3 | 3 | 0 | 9 | Adults/Localised GIST. | 730 | 7 |
Hislop 2011/2012 | SR | Standard search; through October 2010. | To determine the relative benefit (in patients who have acquired resistance to the 400 mg/day imatinib dose) of dose escalation (to either 600 mg/day or 800 mg/day imatinib), sunitinib or best supportive care. | 5 | 3 | 1 | 0 | 1 | 0 | 0 | Adults/ Unresectable and/or metastatic GIST. | 669 | 9 |
Liang 2013 | SRM | Standard search; through June 2012. | To compare surgical and oncologic outcomes of patients with GISTs undergoing laparoscopic resection surgery and open resection surgery. | 17 | 0 | 0 | 0 | 17 | 0 | 0 | Adults/Localised GIST. | 776 | 10 |
Liu 2013 | SRM | Standard search; through June 2012. | The current meta-analysis aimed to determine the efficacy and safety of different doses of imatinib in patients with GISTs and to identify the optimized dose, and to weigh the clinical benefit against the associated toxicity. | 5 | 5 | 0 | 0 | 0 | 0 | 0 | Adults/Unresectable and/or metastatic GIST. | 2008 | 8 |
NICE 2009 | SR | Standard search; through September 2008. | To consider the use of sunitinib malate for the treatment of people with unresectable and/or metastatic gastrointestinal stromal tumours (GIST) after failure of imatinib due to resistance or intolerance. | 2 | 1 | 0 | 0 | 1 | 0 | 0 | Adults/Unresectable and/or metastatic GIST. | 1438 | 7 |
NICE 2014 | SR | Standard search; through April 2014, updated on February 2014. | To consider the use of imatinib for the adjuvant treatment of gastrointestinal stromal tumours. | 16 | 4 | 0 | 0 | 12 | 0 | 0 | Adults/Unresectable and/or metastatic GIST. | 2018 | 8 |
Ohtani 2013 | SRM | Followed PRISMA recommendations; through June 2013. | To evaluate and compare the short- and long-term outcomes of laparoscopic and conventional open surgery for GIST. | 12 | 0 | 0 | 0 | 12 | 0 | 0 | Adults/Localized GIST. | 644 | 8 |
Pelletier 2015 | SRM | Standard search; through July 2012. | To compare the laparoscopic and open surgical resection of gastric GISTs to assess the effectiveness and safety of this minimally invasive technique. | 7 | 0 | 0 | 0 | 6 | 1 | 0 | Adults/Localized GIST. | 330 | 10 |
Wilson 2005 | SR | Standard search; through May 2003. | To assess the clinical and cost-effectiveness of imatinib in the treatment of unresectable and/or metastatic GISTs, relative to current standard treatments. | 15 | 0 | 0 | 6 | 0 | 0 | 9 | Adults/Unresectable and/or metastatic GIST. | 1887 | 9 |
Wu 2014 | SRM | Standard search; through February 2014. | To evaluate the efficacy of second-generation TKIs with regard to progression-free survival and overall survival in patients with advanced GIST. | 3 | 3 | 0 | 0 | 0 | 0 | 0 | Adults/Advanced GIST. | 808 | 10 |
Yang 2012 | SRM | Standard search; through February 2012. | To evaluate the efficacy and safety of two doses of imatinib for patients with GISTs. | 5 | 5 | 0 | 0 | 0 | 0 | 0 | Adults/Unresectable and/or metastatic GIST. | 1861 | 7 |
Zheng 2014 | SRM | Standard search; through May 2012. | To assess existing evidence about the efficacy and safety of laparoscopic resection versus that of open resection for gastric GISTs. | 11 | 0 | 0 | 0 | 11 | 0 | 0 | Adults/Localized GIST. | 495 | 9 |
Zong 2011 | SRM | Standard search; through July 2010. | To evaluate the response to imatinib at different dose levels to identify the better choice for the treatment of patients with GIST. | 3 | 3 | 0 | 0 | 0 | 0 | 0 | Adults/Unresectable and/or metastatic GIST. | 1787 | 9 |